Paratek (formerly Transcept Pharmaceuticals)

Paratek Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing innovative treatments for serious infectious diseases and other difficult-to-treat conditions. The company's lead commercial product is NUZYRA® (omadacycline), an FDA-approved once-daily oral and intravenous tetracycline-class antibiotic for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible bacteria. Omadacycline represents a modernized tetracycline engineered to overcome tetracycline-class resistance mechanisms. Paratek also markets XHANCE®, a prescription nasal spray approved by the U.S. FDA for the treatment of chronic rhinosinusitis with or without nasal polyps in adults. The company is headquartered in King of Prussia, Pennsylvania, and emphasizes ESG principles including environmental stewardship, social responsibility, and good corporate governance.